Homocysteine — is it still an important risk factor for cardiovascular disease?

Cybulska, Barbara; Kłosiewicz−Latoszek, Longina

doi:10.5603/kp.2015.0229

Cited by 16 publications

(7 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In contrast, our results did not put the presence of MTHFR C677T genotype as a strong determinant for mortality, at least in a short follow up of 1 year. Since the patients with this SNP showed a trend to have higher levels of Hcy, belonging to the range of moderately elevated 34 , probably, in this situation, the beneficial effect of reducing Hcy could be confirmed in a more expanded population leading to an expected shrinkage of the standard deviation and reaching significant statistical difference p<0.05.…”

Section: Discussionmentioning

confidence: 78%

Serum Homocysteine Levels and its Methylenetetrahydrofolate Gene (MTHFR) C677t Polymorphism in Patients with Hemodialysis

Pastrana¹,

Alvarado²,

Marenco³

et al. 2017

J. of Medical Sciences

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 78%

Serum Homocysteine Levels and its Methylenetetrahydrofolate Gene (MTHFR) C677t Polymorphism in Patients with Hemodialysis

Pastrana¹,

Alvarado²,

Marenco³

et al. 2017

J. of Medical Sciences

View full text Add to dashboard Cite

show abstract

“… 27 Nevertheless it should be kept in mind that some of these studies were performed in subjects consuming folate fortified food and had a relatively short follow-up. 28 …”

Section: Discussionmentioning

confidence: 99%

Effects of bromocriptine mesylate on homocysteine and high-sensitivity C-reactive protein levels in patients with type-2 diabetes mellitus

Niafar

Pourafkari

Shahsavarinia

et al. 2016

J Cardiovasc Thorac Res

View full text Add to dashboard Cite

Introduction: Quick release bromocriptine (BROM-QR), currently approved for glycemic control, reduces the risk of cardiovascular events in adults with type-2 diabetes mellitus (T2DM). This study evaluates the effect of BROM-QR on homocysteine (HOMC) and high sensitive C-reactive protein (hs-CRP), the biochemical markers of coronary atherosclerosis/inflammation, in patients with uncontrolled T2DM. Methods: In this non-randomized, before-and-after clinical trial, patients with uncontrolled T2DM on stable doses of two oral hypoglycemic agents received BROM-QR for 6 months. The change in serum concentrations of HOMC was the primary endpoint. Anthropometric measurements such as body mass index (BMI) and waist circumference were measured at the baseline and at the completion of treatment along with fasting plasma glucose (FPG), HbA1c, total cholesterol, triglyceride, creatinine and hs-CRP. Multivariate regression analysis was performed to identify factors associated with changes in the levels of HOMC. Results: In 64 patients (46 completed 6 months of treatment), age was 55±7 years and the duration of T2DM was 8.0 ± 4.4 years. On enrollment, mean HbA1c, FPG, hs-CRP and HOMC levels were 9.0± 1.3 percent, 184 ± 42 mg/dL, 3.8± 3.4 mg/dl and 10.8 ± 6.2 micromole/L; respectively. Mean decrease of 0.7 ± 1.1 percent for HbA1c (P = 0.001) and 22 ± 44 mg/dL for FPG was observed (P = 0.002). HOMC levels decreased to 8.5 ± 5.2 micromole/L (P = 0.011) while hs-CRP levels remained unchanged at 3.7 ± 2.9 mg/dL (P = 0.835). Conclusion: While HOMC and HbA1c levels decreased significantly after 6 months of treatment with BROM-QR in patients with T2DM, serum levels of hs-CRP, total cholesterol and triglyceride did not significantly change.

show abstract

“…1 Increased blood homocysteine (Hcy) level independently predicted all-cause and cardiovascular mortality in the general and especially in the older population, 2 and it has been recognised as a risk factor for cardiovascu-The Effects of Certain Gasotransmitters Inhibition on Homocysteine Acutely Induced Changes on Rat Cardiac Acetylcholinesterase Activity lar diseases. 3,4 Different studies [5][6][7][8][9] have demonstrated that increased Hcy concentration was correlated with poor prognosis in patients with acute coronary syndrome, but other studies results were contradictory. 8,[10][11][12][13] Previous study revealed that increased Hcy may be associated with elevated oxidative stress and inhibition of the butyrylcholinesterase (BuChE) activity.…”

Section: Introductionmentioning

confidence: 99%

The effects of certain gasotransmitters inhibition on homocysteine acutely induced changes on rat cardiac acetylcholinesterase activity

Mutavdzin¹,

Lončar-Stojiljković²,

Kostic³

et al. 2019

Scripta Medica

View full text Add to dashboard Cite

Background/Aim: Hyperhomocysteinaemia is linked to higher level of acetylcholinesterase (AChE) in brain, but there is insufficient information on influence of homocysteine (Hcy) and gasotransmitters on cardiac AChE. Thus, the aim of this study was to evaluate the influence of certain gasotransmitter inhibitors in Hcy-induced changes on rat cardiac AChE activity. Methods: Research was performed on 72 male Wistar albino rats distributed into 6 groups: 1) Control group-saline (1 ml 0.9 % NaCl ip); 2) DL-Hcy (8 mmol/kg ip DL homocysteine (DL-Hcy); 3) L-NAME (10 mg/kg ip N ω-Nitro-L-arginine methyl ester (L-NAME), inhibitor of NO production); 4) DL-PAG (50 mg/kg ip DL-propargylglycine (DL-PAG), inhibitor of H2S production); 5) DL-Hcy+L-NAME (8 mmol/ kg ip DL-Hcy + 10 mg/kg ip L-NAME); and 6) DL-Hcy+DL-PAG (8 mmol/kg ip DL-Hcy + 50 mg/kg ip DL-PAG). All tested substances were administered in a single dose, intraperitoneally, 60 minutes before animals' sacrifice. AChE activity was measured in the rats' cardiac tissue homogenate. Results: Administration of Hcy and L-NAME induced significant decrease in AChE activity compared with control condition. Administration of DL-PAG, DL-Hcy+L-NAME and DL-Hcy+DL-PAG did not change AChE activity compared with the control group. Conclusion: The effects of acute Hcy administration on the cardiac AChE activity are partially mediated via interaction with tested gasotransmitters.

show abstract

Homocysteine — is it still an important risk factor for cardiovascular disease?

Cited by 16 publications

References 51 publications

Serum Homocysteine Levels and its Methylenetetrahydrofolate Gene (MTHFR) C677t Polymorphism in Patients with Hemodialysis

Serum Homocysteine Levels and its Methylenetetrahydrofolate Gene (MTHFR) C677t Polymorphism in Patients with Hemodialysis

Effects of bromocriptine mesylate on homocysteine and high-sensitivity C-reactive protein levels in patients with type-2 diabetes mellitus

The effects of certain gasotransmitters inhibition on homocysteine acutely induced changes on rat cardiac acetylcholinesterase activity

Contact Info

Product

Resources

About